Supernus Pharmaceuticals to Acquire Sage Therapeutics, Boosting Neuropsychiatry Portfolio
Supernus Pharmaceuticals is acquiring Sage Therapeutics in a deal valued at up to $795 million, aiming to expand its neuropsychiatry portfolio with the FDA-approved postpartum depression treatment ZURZUVAE and to achieve significant growth and cost synergies by 2026.